---
title: "Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease"
description: "Sarepta Therapeutics Inc :SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASESAREPTA THERAPEUTICS INC - FIRST-IN-"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274823249.md"
published_at: "2026-02-04T13:40:37.000Z"
---

# Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease

> Sarepta Therapeutics Inc :SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASESAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026

Sarepta Therapeutics Inc :

-   SAREPTA THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASE
-   SAREPTA THERAPEUTICS INC - FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026
-   SAREPTA THERAPEUTICS INC: FIRST-IN-HUMAN CLINICAL STUDY OF SRP-1005, KNOWN AS INSIGHTT, IS EXPECTED TO BEGIN IN Q2 OF 2026

### Related Stocks

- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSA Capital Partners LLP 增加了对 Edgewise Therapeutics, Inc. $EWTX 的持股 | GSA Capital Partners LLP 在第三季度将其在 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) 的持股增加了 315.2%，目前持有 113,243 股，价值 184 万美元。其他对冲 | [Link](https://longbridge.com/en/news/276119404.md) |
| Zweig DiMenna Associates LLC 购入了 CareDx, Inc.的 348,400 股股票，股票代码为$CDNA | Zweig DiMenna Associates LLC 在第三季度将其在 CareDx, Inc. (NASDAQ:CDNA) 的持股增加了 153.8%，收购了 348,400 股，使其总持股达到 575,000 股，价值 836 万美 | [Link](https://longbridge.com/en/news/276125724.md) |
| Moderna 因 FDA 对流感疫苗的审查而股价跃升至 20 日移动平均线之上。现在是购买 MRNA 股票的好时机吗？ | Moderna 在 FDA 流感疫苗审查中突破 20 日移动平均线。你应该在这里购买 MRNA 股票吗？ | [Link](https://longbridge.com/en/news/276273938.md) |
| Merit Financial Group LLC 购入了 1,397 股再生元制药公司（Regeneron Pharmaceuticals, Inc.）的股票 $REGN | Merit Financial Group LLC 在第三季度将其在再生元制药的股份增加了 302.4%，新增了 1,397 股，总持股达到 1,859 股，市值为 1,045,000 美元。其他机构投资者也增加了他们的持股。分析师对该股票 | [Link](https://longbridge.com/en/news/276208818.md) |
| 诺华制药的 remibrutinib 成为首个在慢性诱发性荨麻疹（CIndU）中达到 III 期主要终点的治疗方案 | 诺华宣布其选择性口服 BTK 抑制剂 remibrutinib 在治疗慢性诱发性荨麻疹（CIndU）的 III 期 RemIND 试验中取得了积极结果。该试验达到了主要终点，显示出三种 CIndU 类型的显著完全应答率。Remibrutin | [Link](https://longbridge.com/en/news/276201069.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.